Download PDF
Pharmacopsychiatry 2013; 46(01): 16-22
DOI: 10.1055/s-0032-1311627
Original Paper
© Georg Thieme Verlag KG Stuttgart · New York

Treatment of Comorbid Anxiety and Depression with Escitalopram: Results of a Post-Marketing Surveillance Study

G. Laux
1   kbo-Inn-Salzach-Klinikum gGmbH, Wasserburg a. Inn, Germany
,
M. Friede
2   Lundbeck GmbH, Hamburg, Germany
,
W. E. Müller
3   Department of Pharmacology, University of Frankfurt, Frankfurt, Germany
› Author Affiliations
Further Information

Publication History

Publication Date:
30 May 2012 (online)

Also available at
   Permissions and Reprints

Abstract

Introduction:

In this 16-week post-marketing surveillance (PMS) study, antidepressant effects and tolerability of escitalopram was examined in 2 911 patients with comorbid depression and anxiety.

Methods:

Antidepressant effects were assessed using a modified version of the Montgomery-Åsberg depression rating scale (svMADRS), the Hamilton anxiety scale (HAMA) and the hospital anxiety depression scale (HADS-D) and the clinical global impression scale (CGI-S, CGI-I).

Results:

Treatment was completed by 2 718 patients, whose severity of depression decreased from a mean svMADRS total score of 33.0 to 8.9. At the end of the study, the remission rate (svMADRS≤12) was 72.9% and the response rate (≥50% decrease in svMADRS score) was 83.1% (LOCF). Similarly, the severity of anxiety symptoms decreased from a mean HAMA total score of 28.8–8.8; the remission rate (HAMA<10) was 63.9% and the response rate (decrease≥50%) was 80.2%. The most frequent adverse events were nausea (1.6%), agitation (1.1%) and fatigue (0.7%).

Discussion:

Antidepressant effects and good tolerability of escitalopram were confirmed in everyday practice in patients with comorbid depression and anxiety. The high response and remission rates were within the range reported in previous RTC’s of escitalopram vs. comparators or vs. placebo.

Key words

anxiety - depression - escitalopram - comorbidity
 

  • References

  • 1 Gorman JM, Kent JM. SSRIs and SNRIs: broad spectrum of efficacy beyond major depression. J Clin Psychiatry 1999; 60 (Suppl. 04) 33-38
    CrossrefPubMedGoogle Scholar
  • 2 Isaac M. Where are we going with SSRIs?. Eur Neuropsychopharmacol 1999; 9 (Suppl. 03) 101-106
    CrossrefPubMedGoogle Scholar
  • 3 Judd LL, Kessler RC, Paulus MP et al. Comorbidity as a fundamental feature of generalized anxiety disorders: results from the National Comorbidity Study (NCS). Acta Psychiatr Scand 1998; 393 (Suppl) 6-11
    PubMedGoogle Scholar
  • 4 Pollack MH. Comorbid anxiety and depression. J Clin Psychiatry 2005; 66: 22-29
    PubMedGoogle Scholar
  • 5 Moffitt TE, Harrington HL, Caspi A et al. Depression and generalized anxiety disorder. Cumulative and sequential comorbidity in a birth cohort followed prospectively to age 32 years. Arch Gen Psychiatry 2007; 64: 651-660
    PubMedGoogle Scholar
  • 6 Broich K. Anforderungen an klinische Prüfungen mit Arzneimitteln bei Angststörungen. Psychopharmakotherapie 2006; 13: 241-247
    PubMedGoogle Scholar
  • 7 CIPS. Internationale Skalen für Psychiatrie. Beltz Test GmbH, 2005
    PubMed
  • 8 Möller HJ, Schnitker J. Einsatz einer modifizierten MADRS bei depressiven Patienten in einer prospektiven Kohortenstudie. Nervenarzt 2007; 78: 685-690
    CrossrefPubMedGoogle Scholar
  • 9 Allgulander C, Florea I, Huusom AKT. Prevention of relapse in generalized anxiety disorder by escitalopram treatment. Int J Neuropsychopharmacol 2005; 9: 1-11
    CrossrefPubMedGoogle Scholar
  • 10 Burke WJ, Gergel I, Bose A. Fixed-dose trial of the single isomer SSRI escitalopram in depressed outpatients. J Clin Psychiatry 2002; 63: 331-336
    CrossrefPubMedGoogle Scholar
  • 11 Davidson J, Bose A, Korotzer A et al. Escitalopram in the treatment of generalized anxiety disorder: Double-blind, placebo controlled, flexible dose study. Depress Anxiety 2004; 19: 234-240
    CrossrefPubMedGoogle Scholar
  • 12 Lepola UM, Loft H, Reines EH. Escitalopram (10–20 mg/day) is effective and well tolerated in a placebo-controlled study in depression on primary care. Int Clin Psychopharmacol 2003; 18: 211-217
    CrossrefPubMedGoogle Scholar
  • 13 Ninan PT, Ventura D, Wang J. Escitalopram is effective and well tolerated in the treatment of severe depression. Poster presented at the 156th Annual Meeting of the American Psychiatric Association, San Francisco, USA, May 17–22, 2003
    PubMedGoogle Scholar
  • 14 Wade AG, Lemming O, Hedegaard K. Escitalopram 10 mg/day is effective and well-tolerated in a placebo-controlled study in depression in primary care. Int Clin Psychopharmacol 2002; 17: 95-102
    CrossrefPubMedGoogle Scholar
  • 15 Gorman JM, Korotzer A, Su G. Efficacy comparison of escitalopram and citalopram in the treatment of major depressive disorder: pooled analysis of placebo-controlled trials. CNS Spectrums 2002; 7: 40-44
    PubMedGoogle Scholar
  • 16 Kennedy SH, Andersen HF, Thase ME. Escitalopram in the treatment of major depressive disorder: A meta-analysis. Curr Med Res Opin 2009; 25: 161-175
    CrossrefPubMedGoogle Scholar
  • 17 Boulenger P, Hermes A, Huusom AKT et al. Baseline anxiety effect on outcome of SSRI treatment in patients with severe depression: escitalopram vs paroxetine. Curr Med Res Opin 2010; 26: 605-614
    CrossrefPubMedGoogle Scholar
  • 18 Bielski RJ, Bose A, Chang CC. A double-blind comparison of escitalopram and paroxetine in the long-term treatment of generalized anxiety disorder. Ann Clin Psychiatry 2005; 17: 65-69
    CrossrefPubMedGoogle Scholar
  • 19 Kasper S, Stein D, Loft H et al. Escitalopram in the treatment of social anxiety disorder. Randomised, placebo-controlled, flexible-dosage study. Br J Psychiatry 2005; 186: 222-226
    CrossrefPubMedGoogle Scholar
  • 20 Rapaport M, Bose A, Zheng H et al. Escitalopram prevents relapse of depressive episodes. Eur Psychiatry 2002; 17 (0i) S97
    PubMedGoogle Scholar
  • 21 Cipriani A, Barbui C, Geddes JR. Suicide, depression, and antidepressants. BMJ 2005; 330: 373-374
    CrossrefPubMedGoogle Scholar
  • 22 Laux G, Schüler P, Bruns S. Reboxetin in Klinik und Facharztpraxis. Psychopharmakotherapie 2000; 7: 162-167
    PubMedGoogle Scholar
  • 23 Llorca PM, Azorin JM, Despiegel N et al. Efficacy of escitalopram in patients with severe depression: a pooled analysis. Int J Clin Pract 2005; 59: 268-275
    CrossrefPubMedGoogle Scholar
  • 24 Yevtushenko VY, Belous AI, Yevtushenko YG et al. Efficacy and tolerability of escitalopram versus citalopram in major depressive disorder: A 6-week, multicenter, prospective, randomized, double-blind, active-controlled study in adult outpatients. J Clin Ther 2007; 29: 2319-2332
    PubMedGoogle Scholar
  • 25 Winkler D, Pirek E, Klein N et al. Escitalopram bei berufstätigen Menschen. Ergebnisse einer Anwendungsbeobachtung an 2378 Patienten. Psychopharmakotherapie 2006; 13: 142-146
    PubMedGoogle Scholar
  • 26 Möller HJ, Friede M, Schmauß M. Behandlung der Depression mit Escitalopram. Ergebnisse einer großen Anwendungsbeobachtung. Psychopharmakotherapie 2007; 14: 149-156
    PubMedGoogle Scholar
  • 27 Colonna L, Andersen HF, Reines EH. A randomized, double-blind, 24-week study of escitalopram (10 mg/day) versus citalopram (20 mg/day) in primary care patients with major depressive disorder. Curr Med Res Opin 2005; 21: 1659-1668
    CrossrefPubMedGoogle Scholar
  • 28 Montgomery SA, Huusom AKT, Bothmer J. A randomised study comparing escitalopram with venlafaxine XR in primary care patients with major depressive disorder. Neuropsychobiology 2004; 50: 57-64
    CrossrefPubMedGoogle Scholar
  • 29 Moore N, Verdoux H, Fantino B. Prospective, multicentre, randomized, double-blind study of the efficacy of escitalopram versus citalopram in outpatient treatment of major depressive disorder. Int Clin Psychopharmacol 2005; 20: 131-137
    CrossrefPubMedGoogle Scholar
  • 30 Goodman WK, Bose A, Wang Q. Treatment of generalized anxiety disorder with escitalopram: pooled results from double-blind, placebo-controlled trials. J Affect Dis 2005; 87: 161-167
    CrossrefPubMedGoogle Scholar